Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…